$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000128581916000024 Filed on November 09, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$12.91M	$11.29M	$3.259M
YoY Change	93.33%	246.39%	1422.9%
Cost Of Revenue	$380.0K	$378.0K	$248.0K
YoY Change	-9.52%	52.42%
Gross Profit	$12.53M	$10.91M	$3.011M
YoY Change	100.16%	262.37%	1307.01%
Gross Profit Margin	97.09%	96.65%	92.39%
Selling, General & Admin	$11.84M	$10.46M	$9.050M
YoY Change	25.96%	15.58%	62.48%
% of Gross Profit	94.49%	95.87%	300.56%
Research & Development	$12.54M	$12.49M	$13.26M
YoY Change	-15.84%	-5.82%	12.67%
% of Gross Profit	100.08%	114.49%	440.52%
Depreciation & Amortization	$90.00K	$90.00K	$50.00K
YoY Change	80.0%	80.0%	-44.44%
% of Gross Profit	0.72%	0.82%	1.66%
Operating Expenses	$24.76M	$23.33M	$22.56M
YoY Change	0.19%	3.4%	30.06%
Operating Profit	-$11.86M	-$12.04M	-$19.30M
YoY Change	-34.27%	-37.63%	12.66%
Interest Expense	-$2.450M	$2.135M	$871.0K
YoY Change	202.47%	145.12%	-7.73%
% of Operating Profit
Other Income/Expense, Net	$270.0K	$211.0K	$251.0K
YoY Change	-20.59%	-15.94%	-200.0%
Pretax Income	-$19.63M	-$13.96M	-$19.92M
YoY Change	-1.01%	-29.92%	8.67%
Income Tax
% Of Pretax Income
Net Earnings	-$19.63M	-$13.96M	-$19.92M
YoY Change	-0.98%	-29.91%	8.7%
Net Earnings / Revenue	-152.13%	-123.68%	-611.26%
Basic Earnings Per Share
Diluted Earnings Per Share	-$454.1K	-$340.0K	-$525.3K
COMMON SHARES
Basic Shares Outstanding	42.92M shares	39.29M shares	37.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.30M	$47.40M	$35.00M
YoY Change	60.07%	35.43%	60.55%
Cash & Equivalents	$2.224M	$10.30M	$601.0K
Short-Term Investments	$43.10M	$37.10M	$34.40M
Other Short-Term Assets	$1.800M	$1.400M	$99.00K
YoY Change	-5.26%	1314.14%	-33.11%
Inventory	$1.128M	$1.396M	$445.0K
Prepaid Expenses	$1.766M	$1.355M	$1.410M
Receivables	$12.00M	$10.50M	$2.500M
Other Receivables	$100.0K	$0.00	$0.00
Total Short-Term Assets	$60.26M	$60.65M	$39.46M
YoY Change	62.23%	53.69%	68.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.181M	$1.206M	$808.0K
YoY Change	24.19%	49.26%	-4.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$73.00K	$467.0K
YoY Change	-100.0%	-84.37%	14.46%
Total Long-Term Assets	$7.016M	$12.11M	$1.954M
YoY Change	-40.79%	519.96%	1.09%
TOTAL ASSETS
Total Short-Term Assets	$60.26M	$60.65M	$39.46M
Total Long-Term Assets	$7.016M	$12.11M	$1.954M
Total Assets	$67.28M	$72.76M	$41.42M
YoY Change	37.32%	75.68%	63.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.519M	$3.985M	$4.575M
YoY Change	-60.81%	-12.9%	10.08%
Accrued Expenses	$13.35M	$11.88M	$8.121M
YoY Change	36.94%	46.31%	29.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$198.0K	$190.0K	$9.577M
YoY Change	171.23%	-98.02%	139.96%
Total Short-Term Liabilities	$16.07M	$16.06M	$22.27M
YoY Change	-1.12%	-27.91%	54.71%
LONG-TERM LIABILITIES
Long-Term Debt	$79.51M	$70.29M	$18.97M
YoY Change	59.76%	270.45%	-33.54%
Other Long-Term Liabilities	$9.100M	$9.200M	$9.200M
YoY Change	-1.09%	0.0%	3.37%
Total Long-Term Liabilities	$79.51M	$70.29M	$18.97M
YoY Change	59.76%	270.45%	-33.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.07M	$16.06M	$22.27M
Total Long-Term Liabilities	$79.51M	$70.29M	$18.97M
Total Liabilities	$95.58M	$86.35M	$41.25M
YoY Change	44.77%	109.34%	-3.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$469.9M	-$450.3M	-$383.3M
YoY Change	16.56%	17.46%	24.72%
Common Stock	$438.0K	$429.0K	$380.0K
YoY Change	15.26%	12.89%	11.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$37.45M	-$22.77M	-$9.004M
YoY Change
Total Liabilities & Shareholders Equity	$67.28M	$72.76M	$41.42M
YoY Change	37.32%	75.68%	63.74%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$19.63M	-$13.96M	-$19.92M
YoY Change	-0.98%	-29.91%	8.7%
Depreciation, Depletion And Amortization	$90.00K	$90.00K	$50.00K
YoY Change	80.0%	80.0%	-44.44%
Cash From Operating Activities	-$10.86M	-$11.22M	-$14.59M
YoY Change	-34.58%	-23.1%	-8.47%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$50.00K	-$80.00K
YoY Change	0.0%	-37.5%	700.0%
Acquisitions
YoY Change
Other Investing Activities	-$5.960M	-$20.50M	$14.48M
YoY Change	-179.47%	-241.57%	-2.82%
Cash From Investing Activities	-$6.020M	-$20.54M	$14.42M
YoY Change	-180.91%	-242.44%	-3.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$37.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.800M	37.47M	-1.790M
YoY Change	-11.29%	-2193.3%	-762.96%
NET CHANGE
Cash From Operating Activities	-10.86M	-11.22M	-14.59M
Cash From Investing Activities	-6.020M	-20.54M	14.42M
Cash From Financing Activities	8.800M	37.47M	-1.790M
Net Change In Cash	-8.080M	5.710M	-1.960M
YoY Change	-1163.16%	-391.33%	148.1%
FREE CASH FLOW
Cash From Operating Activities	-$10.86M	-$11.22M	-$14.59M
Capital Expenditures	-$50.00K	-$50.00K	-$80.00K
Free Cash Flow	-$10.81M	-$11.17M	-$14.51M
YoY Change	-34.68%	-23.02%	-8.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42915928	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
	dei	Trading Symbol TradingSymbol	OMER
CY2015Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1108000	USD
CY2016Q3	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1933000	USD
CY2015Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	2973000	USD
CY2016Q3	omer	Accrued Contract Research Costs AccruedContractResearchCosts	2360000	USD
	omer	Long Term Purchase Commitment Termination Fee LongTermPurchaseCommitmentTerminationFee	912000	USD
	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	2571000	USD
	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	2200000	USD
	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	2248000	USD
	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	1326773	shares
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6428000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3985000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9752000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11882000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2400000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2362000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	376528000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	427054000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	758000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9506065	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9437283	shares
CY2015Q4	us-gaap	Assets Assets	48995000	USD
CY2016Q3	us-gaap	Assets Assets	72763000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	37146000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	60649000	USD
CY2015Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	26898000	USD
CY2016Q3	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	37144000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	388000	USD
CY2015Q4	us-gaap	Cash Cash	1400000	USD
CY2016Q3	us-gaap	Cash Cash	10300000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	354000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	601000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1365000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10297000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	247000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8932000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	47400000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	749250	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38040891	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42910489	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38040891	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42910489	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	380000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	429000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19921000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55270000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13962000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47113000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	248000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	624000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	378000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1032000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9207000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9189000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	161000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	211000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2590000	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3413000	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14300000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9048000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25926000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10457000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31942000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	721000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-303000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-123000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	924000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	282000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-685000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-124000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	18000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2118000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3940000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	0	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	156000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	871000	USD
	us-gaap	Interest Expense InterestExpense	2765000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	2135000	USD
	us-gaap	Interest Expense InterestExpense	5367000	USD
	us-gaap	Interest Paid InterestPaid	2141000	USD
	us-gaap	Interest Paid InterestPaid	3629000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	221000	USD
CY2016Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	54000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	472000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	1396000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	93000	USD
CY2016Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	101000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000	USD
CY2016Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1241000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48995000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72763000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16253000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16057000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	73000	USD
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	190000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49769000	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	70289000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76909000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59897000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28053000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10324000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48609000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40641000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-19921000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55270000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-13962000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47113000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	22560000	USD
	us-gaap	Operating Expenses OperatingExpenses	60032000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	23327000	USD
	us-gaap	Operating Expenses OperatingExpenses	71131000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19301000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-53198000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12038000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42419000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1814000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	219000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	251000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	693000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	211000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	673000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	659000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1195000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	79416000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	58121000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	187000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	78000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1894000	USD
CY2016Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1355000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79100000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37300000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79076000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38003000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	19864000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	51550000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	47875000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	951000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1206000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6517000	USD
CY2016Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	10457000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4738000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	62000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13264000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33482000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12492000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38157000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	10679000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	10835000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-403142000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450255000	USD
CY2015Q3	us-gaap	Revenue From Grants RevenueFromGrants	15000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	227000	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	173000	USD
CY2015Q3	us-gaap	Revenues Revenues	3259000	USD
	us-gaap	Revenues Revenues	6834000	USD
CY2016Q3	us-gaap	Revenues Revenues	11289000	USD
	us-gaap	Revenues Revenues	28712000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3244000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6607000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11289000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	28539000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2376000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7273000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2535000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9566000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6930249	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.69
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	90186	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.99
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1694155	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26721000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8310235	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9336681	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.97
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.69
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	26599000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9094553	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.61
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.85
CY2015Q1	us-gaap	Share Price SharePrice	20.03
CY2016Q3	us-gaap	Share Price SharePrice	11.50
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25521000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M27D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M3D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3400000	shares
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3500000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	577523	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-26234000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	-22772000	USD
CY2015	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37923353	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37417915	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41058754	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39518128	shares
	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record revenue from OMIDRIA sales when the product is delivered to our wholesalers.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled. Product sales to wholesalers are not recorded if we determine that the wholesaler’s on-hand OMIDRIA inventory, based on inventory information we regularly receive from our wholesalers, exceeds approximately eight weeks of projected demand. </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001285819-16-000024-index-headers.html	Edgar Link	pending
0001285819-16-000024-index.html	Edgar Link	pending
0001285819-16-000024.txt	Edgar Link	pending
0001285819-16-000024-xbrl.zip	Edgar Link	pending
ex101_20160930.htm	Edgar Link	pending
ex102_20160930.htm	Edgar Link	pending
ex121_20160930.htm	Edgar Link	pending
ex311_20160930.htm	Edgar Link	pending
ex312_20160930.htm	Edgar Link	pending
ex321_20160930.htm	Edgar Link	pending
ex322_20160930.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
omer-20160930.xml	Edgar Link	completed
omer-20160930.xsd	Edgar Link	pending
omer-20160930x10q.htm	Edgar Link	pending
omer-20160930_cal.xml	Edgar Link	unprocessable
omer-20160930_def.xml	Edgar Link	unprocessable
omer-20160930_lab.xml	Edgar Link	unprocessable
omer-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2016 Q4 Form 10-Q Financial Statement

#000128581916000024 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2016 Q4 Form 10-Q Financial Statement

#000128581916000024 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer